Please login to the form below

Not currently logged in
Email:
Password:

dulaglutide

This page shows the latest dulaglutide news and features for those working in and with pharma, biotech and healthcare.

Novo bolstered by new diabetes, obesity products

Novo bolstered by new diabetes, obesity products

Despite facing tough competition from its class rivals, particularly first-to-market Trulicity (dulaglutide) from Eli Lilly, Ozempic has continued to be a source of growth for Novo.

Latest news

More from news
Approximately 2 fully matching, plus 45 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics